{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"tmem199-cdg","columns":[{"gene":"","key":"population-53b4e0987c5c4077f0a0","label":"Congenital disorder of glycosylation, type IIp","mondoId":"MONDO:0014790","onsetQualifier":null,"originColumnKey":"MONDO:0014790/OMIM:616829","originalViews":[{"key":"MONDO:0014790/OMIM:616829","label":"Congenital disorder of glycosylation, type IIp","scopeLabel":"OMIM:616829","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["05501a8d112f8b6f505a88a3520a6d778934cf07f30de28075c4645d01517fbc","06a0edce33673fe4d754a06a4273db647fc110f14f5ae76f7f0cb6084fba7b07","14d4db65de26ce0d00cb2c253934eba9738fef8100db6cfb2c68d9c7cdf2da76","169987967e01b90f3b5ece4554cabfdcabbe1d5cddc838b29c8adb9022c36dc3","1e13c34f0ffb079681413b78ea00d42ce71a62bf6b4b7b5b7c9aa73addd03b97","2bc908f8d71ef3f9ea8982d2004e8f88ed038086e3afb6a8e23e3da5d2fdfebc","306e5a1dc5502de2582ac4a3e7b43380dce49b37e9380287cbaa3ef4305cdb54","3d412a93c6e1b5f46a8920d2b783161eebf581255df9998b93a52962e34662a9","442df2535d1ebc06c07947fb0acb35501ba8ea83e4c0189fe2777c39ed340f0e","5893d72a2613518764823cd1aa639fdcbef341116836d968ad296563cc03b668","5d7514ceb9de2e2de0e667275d91a59f5894542cc9ee2105489e14dc76832d37","8da933b5d5fd981ebbeb95dcbe051723e33199dc12df0fd394ba89e3d9a86c48","acf10ba53163d75b8c8e51ec2a1d4473b750098a4d05a5e7dc5ea11fc419544a","beff4c56ada72bb5f5048283f87de8f3122062c3a679d7463aa424cfe942f3f8","bfa2dd43cee4822f0bdd1a490ef64dd60ec365f81bf480f40dda69b22c58a89d","ca0e764975bd28d4d0956a0c49b18caee0fe2b12794fbc5ab102d022bd7a1ab4","e20177f043db053164b9645f18dffd95fdc6a015dac0326cc426cd497ac7b036","e79082e0fd273ca741b99acf6744b2fbe279fc976cf63e97902a53fc460657c3","ea1034d15e3e4a20427acc18da22572d3c2a756c7a3deab4b9ddd27e68b82e19"],"recordQualifiers":{},"scopeLabel":"OMIM:616829","sourceIds":["OMIM:616829"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-53b4e0987c5c4077f0a0"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0012347","HP:0012358","HP:0025321","HP:0010837","HP:0011967","HP:0001410","HP:0031964"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":18,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":19,"sourceGroups":{"omim":1,"published":18}},"features":[{"hpoId":"HP:0012347","label":"Abnormal protein N-linked glycosylation","primary":true},{"hpoId":"HP:0012358","label":"Abnormal protein O-linked glycosylation","primary":true},{"hpoId":"HP:0025321","label":"Copper accumulation in liver","primary":true},{"hpoId":"HP:0010837","label":"Decreased circulating ceruloplasmin concentration","primary":true},{"hpoId":"HP:0011967","label":"Decreased circulating copper concentration","primary":true},{"hpoId":"HP:0001410","label":"Decreased liver function","primary":true},{"hpoId":"HP:0031964","label":"Elevated circulating alanine aminotransferase concentration","primary":true},{"hpoId":"HP:0003155","label":"Elevated circulating alkaline phosphatase concentration","primary":false},{"hpoId":"HP:0031956","label":"Elevated circulating aspartate aminotransferase concentration","primary":false},{"hpoId":"HP:0003236","label":"Elevated circulating creatine kinase activity","primary":false},{"hpoId":"HP:0002910","label":"Elevated circulating hepatic transaminase concentration","primary":false},{"hpoId":"HP:0003141","label":"Elevated circulating LDL-C concentration","primary":false},{"hpoId":"HP:0001263","label":"Global developmental delay","primary":false},{"hpoId":"HP:0001395","label":"Hepatic fibrosis","primary":false},{"hpoId":"HP:0001397","label":"Hepatic steatosis","primary":false},{"hpoId":"HP:0002240","label":"Hepatomegaly","primary":false},{"hpoId":"HP:0003124","label":"Hypercholesterolemia","primary":false},{"hpoId":"HP:0001252","label":"Hypotonia","primary":false},{"hpoId":"HP:0012301","label":"Type II transferrin isoform profile","primary":false}],"ledeHtml":"A rare congenital disorder of glycosylation characterized by chronic, non-progressive liver disease, manifesting as mild steatosis with elevated serum transaminases and alkaline phosphatase, hypercholesterolemia, and decreased coagulation factors and ceruloplasmin. Transferrin glycosylation pattern is consistent with a type 2 congenital disorder of glycosylation. Liver biopsy may show mild non-progressive fibrosis. Patients usually remain asymptomatic, although delayed psychomotor development and hypotonia have been reported in single cases.","mondoId":"MONDO:0014790","node":{"canonicalSlug":"tmem199-cdg","comparisons":[{"documentSha256":"b848d28522b43aab84210e2dd9625192484037a4c60be549db09ebb8dd84939d","key":"legacy-tmem199-cdg","kind":"legacy","label":"TMEM199-CDG","memberIds":["MONDO:0014790"],"mondoId":"MONDO:0014790","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/tmem199-cdg.b848d28522b43aab84210e2dd9625192484037a4c60be549db09ebb8dd84939d.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"summary","independentCorroborationEstablished":false,"matchMethod":"automatic-identity-and-attribution","name":"TMEM199-CDG","originalSourceId":"ORPHA:466703","paragraphs":["A rare congenital disorder of glycosylation characterized by chronic, non-progressive liver disease, manifesting as mild steatosis with elevated serum transaminases and alkaline phosphatase, hypercholesterolemia, and decreased coagulation factors and ceruloplasmin. Transferrin glycosylation pattern is consistent with a type 2 congenital disorder of glycosylation. Liver biopsy may show mild non-progressive fibrosis. Patients usually remain asymptomatic, although delayed psychomotor development and hypotonia have been reported in single cases."],"rawAttribution":"ORPHA:466703","reviewed":null,"scope":"exact","source":"GARD","sourceRelease":"2026-10-21T17:02:57Z","upstream":"ORPHA:466703","url":"https://rarediseases.info.nih.gov/diseases/17825"},"ownColumnKeys":["population-53b4e0987c5c4077f0a0"],"publication":"published","relationships":[{"kind":"parent","label":"congenital disorder of glycosylation type II","mondoId":"MONDO:0005501","slug":"congenital-disorder-of-glycosylation-type-ii"},{"kind":"parent","label":"disorder of multiple glycosylation","mondoId":"MONDO:0017749","slug":null}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"pending"},"records":[{"frequencyKind":"count","key":"05501a8d112f8b6f505a88a3520a6d778934cf07f30de28075c4645d01517fbc","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"7/7","hpo_id":"HP:0003155","is_excluded":false,"label":"Elevated circulating alkaline phosphatase concentration","onset_id":null,"reference":"PMID:29321044;PMID:26833330","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"06a0edce33673fe4d754a06a4273db647fc110f14f5ae76f7f0cb6084fba7b07","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"7/7","hpo_id":"HP:0031956","is_excluded":false,"label":"Elevated circulating aspartate aminotransferase concentration","onset_id":null,"reference":"PMID:29321044;PMID:26833330","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"14d4db65de26ce0d00cb2c253934eba9738fef8100db6cfb2c68d9c7cdf2da76","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"4/4","hpo_id":"HP:0012347","is_excluded":false,"label":"Abnormal protein N-linked glycosylation","onset_id":null,"reference":"PMID:26833330","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"169987967e01b90f3b5ece4554cabfdcabbe1d5cddc838b29c8adb9022c36dc3","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"3/4","hpo_id":"HP:0012358","is_excluded":false,"label":"Abnormal protein O-linked glycosylation","onset_id":null,"reference":"PMID:26833330","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"1e13c34f0ffb079681413b78ea00d42ce71a62bf6b4b7b5b7c9aa73addd03b97","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"6/7","hpo_id":"HP:0003124","is_excluded":false,"label":"Hypercholesterolemia","onset_id":null,"reference":"PMID:29321044;PMID:26833330","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"2bc908f8d71ef3f9ea8982d2004e8f88ed038086e3afb6a8e23e3da5d2fdfebc","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"7/7","hpo_id":"HP:0010837","is_excluded":false,"label":"Decreased circulating ceruloplasmin concentration","onset_id":null,"reference":"PMID:29321044;PMID:26833330","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"306e5a1dc5502de2582ac4a3e7b43380dce49b37e9380287cbaa3ef4305cdb54","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"5/5","hpo_id":"HP:0001397","is_excluded":false,"label":"Hepatic steatosis","onset_id":null,"reference":"PMID:29321044;PMID:26833330","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"3d412a93c6e1b5f46a8920d2b783161eebf581255df9998b93a52962e34662a9","raw":{"aspect":"P","body_system":"digestive","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"5/7","hpo_id":"HP:0001395","is_excluded":false,"label":"Hepatic fibrosis","onset_id":null,"reference":"PMID:29321044;PMID:26833330","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"442df2535d1ebc06c07947fb0acb35501ba8ea83e4c0189fe2777c39ed340f0e","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"1/7","hpo_id":"HP:0001263","is_excluded":false,"label":"Global developmental delay","onset_id":null,"reference":"PMID:29321044;PMID:26833330","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"5893d72a2613518764823cd1aa639fdcbef341116836d968ad296563cc03b668","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"4/4","hpo_id":"HP:0002910","is_excluded":false,"label":"Elevated circulating hepatic transaminase concentration","onset_id":null,"reference":"PMID:26833330","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"5d7514ceb9de2e2de0e667275d91a59f5894542cc9ee2105489e14dc76832d37","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"3/3","hpo_id":"HP:0025321","is_excluded":false,"label":"Copper accumulation in liver","onset_id":null,"reference":"PMID:29321044;PMID:26833330","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"8da933b5d5fd981ebbeb95dcbe051723e33199dc12df0fd394ba89e3d9a86c48","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"1/7","hpo_id":"HP:0001252","is_excluded":false,"label":"Hypotonia","onset_id":null,"reference":"PMID:29321044;PMID:26833330","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"acf10ba53163d75b8c8e51ec2a1d4473b750098a4d05a5e7dc5ea11fc419544a","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"7/7","hpo_id":"HP:0012301","is_excluded":false,"label":"Type II transferrin isoform profile","onset_id":null,"reference":"PMID:29321044;PMID:26833330","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"beff4c56ada72bb5f5048283f87de8f3122062c3a679d7463aa424cfe942f3f8","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"7/7","hpo_id":"HP:0031964","is_excluded":false,"label":"Elevated circulating alanine aminotransferase concentration","onset_id":null,"reference":"PMID:29321044;PMID:26833330","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"bfa2dd43cee4822f0bdd1a490ef64dd60ec365f81bf480f40dda69b22c58a89d","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"6/7","hpo_id":"HP:0003141","is_excluded":false,"label":"Elevated circulating LDL-C concentration","onset_id":null,"reference":"PMID:29321044;PMID:26833330","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"ca0e764975bd28d4d0956a0c49b18caee0fe2b12794fbc5ab102d022bd7a1ab4","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"3/3","hpo_id":"HP:0011967","is_excluded":false,"label":"Decreased circulating copper concentration","onset_id":null,"reference":"PMID:29321044","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"e20177f043db053164b9645f18dffd95fdc6a015dac0326cc426cd497ac7b036","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"3/3","hpo_id":"HP:0003236","is_excluded":false,"label":"Elevated circulating creatine kinase activity","onset_id":null,"reference":"PMID:29321044","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"e79082e0fd273ca741b99acf6744b2fbe279fc976cf63e97902a53fc460657c3","raw":{"aspect":"P","body_system":"digestive","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0001410","is_excluded":false,"label":"Decreased liver function","onset_id":null,"reference":"OMIM:616829","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"ea1034d15e3e4a20427acc18da22572d3c2a756c7a3deab4b9ddd27e68b82e19","raw":{"aspect":"P","body_system":"digestive","disease_id":"OMIM:616829","disease_name":"Congenital disorder of glycosylation, type IIp","evidence":"PCS","frequency_raw":"3/7","hpo_id":"HP:0002240","is_excluded":false,"label":"Hepatomegaly","onset_id":null,"reference":"PMID:29321044;PMID:26833330","source_release":"2026-06-23"},"sourceGroups":["published"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/17825\" rel=\"noreferrer\">GARD</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-identity-and-attribution</dd><dt>Upstream attribution</dt><dd>ORPHA:466703</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>A rare congenital disorder of glycosylation characterized by chronic, non-progressive liver disease, manifesting as mild steatosis with elevated serum transaminases and alkaline phosphatase, hypercholesterolemia, and decreased coagulation factors and ceruloplasmin. Transferrin glycosylation pattern is consistent with a type 2 congenital disorder of glycosylation. Liver biopsy may show mild non-progressive fibrosis. Patients usually remain asymptomatic, although delayed psychomotor development and hypotonia have been reported in single cases.</p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/17825\" rel=\"noreferrer\">GARD</a></p>","key":"overview","title":"Overview"}],"sharedSources":[],"slug":"tmem199-cdg","sourceDocuments":[{"name":"GARD: TMEM199-CDG","reviewed":null,"source_release":"2026-10-21T17:02:57Z","url":"https://rarediseases.info.nih.gov/diseases/17825"}],"sourceNote":"","synonyms":["carbohydrate deficient glycoprotein syndrome type IIp","CDG syndrome type IIp","CDG-IIp","CDG2P","congenital disorder of glycosylation type 2p","congenital disorder of glycosylation type IIp","congenital disorder of glycosylation, type IIp"],"takeawayHtml":"","title":"TMEM199-CDG"},"schemaVersion":1}
